Recursion Pharmaceuticals
AI-driven drug discovery using cellular imaging and multi-omics data
Recursion's validated platform and clinical pipeline make it a strong bet for pharma partners investing in AI-driven drug discovery. The enterprise-only access limits flexibility, but for those able to commit, the depth of data and end-to-end capability is unmatched.
Verified 18d ago · liveness 75/100 · cite: rightaichoice.com/tools/recursion-pharma
- Large pharmaceutical companies seeking AI-driven partnerships for oncology and rare disease pipelines
- Investors interested in TechBio with a validated platform and clinical-stage assets
- Computational biology teams requiring high-quality multi-omics data for drug discovery
- Organizations with long development timelines and appetite for first-in-class therapies
- Early-stage startups needing low-cost, self-serve AI drug discovery tools
- Academic labs looking for open-source or freemium access to drug discovery AI
- Therapies outside Recursion's focus areas (currently oncology and rare diseases)
We scan live Reddit threads, YouTube comments, X posts, G2 reviews and other communities — and hand you an honest verdict in under a minute.
- Honest verdict, not marketing
- Real pros & cons from real users
- Attributed quotes with receipts
3 free scans · no card needed
Skip Recursion if you are a small startup or academic lab needing affordable, self-serve AI drug discovery tools without enterprise partnership commitments.
Custom partnership pricing; no published tiers or starting prices
Recursion's pricing is only available through custom enterprise partnerships, making it suitable for large pharma but inaccessible for smaller players. Competitors like Insilico Medicine offer more flexible engagement models, while Atomwise has grant-based access for academics.
In short
Recursion Pharmaceuticals — AI-driven drug discovery using cellular imaging and multi-omics data. Best for Large pharmaceutical companies seeking AI-driven partnerships for oncology and rare disease pipelines, Investors interested in TechBio with a validated platform and clinical-stage assets, Computational biology teams requiring high-quality multi-omics data for drug discovery. Contact Sales pricing.
Viability Score
How likely is Recursion Pharmaceuticals to still be operational in 12 months? Based on 4 signals — momentum (how recently it shipped), wrapper dependency, revenue model, and web presence.
Last calculated: July 2026
How we score →Key Features
- AI-driven target identification using cellular imaging
- Proprietary dataset >50 petabytes (phenomics, transcriptomics, proteomics, ADME)
- Recursion Operating System (Recursion OS) platform
- Automated wet lab with robotics and computer vision
- Machine learning models for molecule design and optimization
- Clinical pipeline with Phase 1/2 and IND-enabling programs
- BioHive-2 supercomputer (NVIDIA collaboration)
- De-identified patient data integration
- End-to-end drug discovery from hit identification to clinical trials
- Focus on first-in-class and best-in-class medicines
About Recursion Pharmaceuticals
Recursion Pharmaceuticals is a clinical-stage TechBio company that combines AI, cellular imaging, and one of the largest proprietary biological datasets (>50 petabytes) to accelerate drug discovery. Its platform, the Recursion Operating System (Recursion OS), integrates phenomics, transcriptomics, proteomics, and de-identified patient data with machine learning models and an automated wet lab. The system enables rapid target identification, molecule design, and preclinical development, significantly reducing the time and cost from hit identification to IND-enabling studies. Recursion's pipeline includes multiple oncology and rare disease candidates, such as REC-4881 (Phase 1b/2 positive results for solid tumors) and REC-3565 (Phase 1 for B-cell lymphomas). The company partners with pharmaceutical leaders and NVIDIA (co-developed BioHive-2 supercomputer). Compared to other AI drug discovery platforms like Insilico Medicine or Atomwise, Recursion offers a more comprehensive end-to-end approach with a unique cellular imaging foundation and a large-scale proprietary dataset. However, access is primarily through enterprise partnerships, making it less suitable for early-stage startups or academic labs seeking flexible, low-cost engagements.
Behind the Verdict
Recursion isn't a self-service AI tool you can test with a credit card. It's an enterprise platform built for deep-pocketed pharma partners who can invest in long-term collaborations. The proprietary dataset (>50 petabytes) and automated wet lab give it a unique data moat that competitors like Insilico or Atomwise can't easily replicate. Where it truly shines is in the breadth of biological data—phenomics, transcriptomics, proteomics, ADME, de-identified patient data—all feeding into a continuous learning loop. The BioHive-2 supercomputer, co-developed with NVIDIA, provides the compute to process that data at scale. On the clinical front, Recursion has multiple candidates in Phase 1/2, including REC-4881 with positive results in solid tumors. That's real validation. But the catch is access: this is not a platform you can license for a single project. Partnerships require significant commitment, and the focus is on oncology and rare diseases—so if you're in other therapeutic areas, you're out of luck. For early-stage startups or academic labs, the cost and complexity are prohibitive. Our take: if you're a large pharma company with a high-risk, high-reward pipeline, Recursion is worth the investment. For everyone else, look elsewhere.
Researching Recursion Pharmaceuticals? Get your full AI stack in 60 seconds.
Free, no signup — tell us your goal and get tools matched to your budget & existing stack.
Real-world workflow fit
Concrete scenarios for the personas Recursion Pharmaceuticals actually fits — and what changes day-one when you adopt it.
A pharmaceutical company wants to identify novel targets for an oncology program. Recursion uses its cellular imaging dataset and AI models to discover and validate new targets within months.
Outcome: Target identification accelerated from years to months, with higher confidence due to multi-omics validation, enabling faster entry into preclinical development.
A biotech firm needs to optimize a lead compound for a rare disease. Recursion's platform screens millions of compounds using automated wet lab and ML, delivering optimized candidates with improved selectivity.
Outcome: Lead optimization completed in weeks instead of months, with reduced attrition risk, moving the candidate toward IND-enabling studies faster.
An investor wants to assess Recursion's platform for potential portfolio company partnership. Recursion provides a demonstration of its OS, dataset size, and pipeline progress.
Outcome: Investor gains confidence in Recursion's data moat and clinical validation, leading to strategic investment or partnership recommendation.
Use Cases
- Identifying novel drug targets for oncology using cellular imaging
- Accelerating hit-to-lead for rare diseases with multi-omics data
- Optimizing lead compounds using machine learning models
- Designing molecules for first-in-class treatments
Models Under the Hood
as of 2026-07-14
Limitations
- Recursion's platform is only available through enterprise partnerships, with no public pricing or self-service access.
- The high cost and custom nature of partnerships may exclude smaller organizations.
- Focused on early-stage discovery, not clinical-stage development.
- No standalone SaaS product for individual researchers.
as of 2026-06-24
Where the pricing makes sense
The company stage and team size where Recursion Pharmaceuticals's pricing actually pencils out — and where peers do it cheaper.
Recursion's pricing is only available through custom enterprise partnerships, making it suitable for large pharma but inaccessible for smaller players. Competitors like Insilico Medicine offer more flexible engagement models, while Atomwise has grant-based access for academics.
Setup time & first value
How long it actually takes to get something useful out of Recursion Pharmaceuticals — broken out by persona, not the marketing-page minute.
For enterprise partners, initial setup includes data integration, model training, and wet lab protocol alignment, typically taking 3-6 months before first results. Recursion's team collaborates closely to customize the workflow.
Resources & Guides
Tutorials & Learning
Official links
Tools that pair well with Recursion Pharmaceuticals
Common stack mates teams adopt alongside Recursion Pharmaceuticals, with the specific reason each pairing earns its keep.
Alternatives to Recursion Pharmaceuticals
View allFrequently Asked Questions
Categories
Best-of guides
Used Recursion Pharmaceuticals? Help shape our editorial sentiment research.